EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Genetic susceptibility to severe immune-related adverse events from immune checkpoint inhibitors

Yiqing Huang, Joseph J. Zhao, Alvin Wong, Sen Hee Tay, Yu Yang Soon, Yvonne Ang, Chris Lixian Tan, Samantha Peiling Yang, Adrian C. L. Kee, Mark D. Muthiah, Kay W. P. Ng, Li-Ling Tan und 23 weitere

Cancer Immunology, Immunotherapy · 18.11.2026

DOI: 10.1007/s00262-026-04640-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 18.11.2026. Verfasst von Yiqing Huang und 34 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NMRC Clinician-Scientist Individual Research Grant New Investigator Grant, National University Hospital System Seed Fund 2022, NMRC Centre Grant Programme.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The etiology and pathogenesis of immune-related adverse events (irAEs) remain poorly understood. Progress has been limited by the rarity and heterogeneity of severe irAEs, small cohorts, and underrepresentation of Asian populations. The unpredictability of severe irAEs hinders effective pre-treatment risk stratification. We sought to identify germline genetic determinants of severe irAEs in an Asian cohort of cancer patients. We prospectively recruited 505 cancer patients of Asian ancestry treated with immune checkpoint inhibitors (ICIs) across two tertiary institutions in Singapore. Patients experiencing lower-grade irAEs (Grades 1–2) were excluded from the association analysis to enable a direct comparison between severe cases and unaffected controls. Of 330 patients comparing Cases (NCI-CTCAEv5 ≥ Grade 3 IrAE) and Controls (without irAE), a multi-ethnic pharmacogenomic genome-wide association study (GWAS) was performed across more than 18 cancer subtypes. To complement the agnostic GWAS, an exploratory candidate gene analysis was also performed. LINC01192 rs146525069 was identified as a candidate variant associated with severe irAEs (allele frequency 10.91% in Cases vs 0.73% in Controls, P = 3.51 × 10 −8 , OR = 24.81 (6.92–88.92)). Exploratory candidate gene analysis revealed four polymorphic variants in genes linked to inflammatory and autoimmune diseases: TNF rs1800629 ( P = 0.0044; OR = 2.48; 95% CI = 1.36–4.52), PTPN2 rs1893217 ( P = 0.0117; OR = 1.79; 95% CI = 1.15–2.79), PTPN2 rs2542151 ( P = 0.0195; OR = 1.71; 95% CI = 1.10–2.67) and ROBO1 rs162263 ( P = 0.0480; OR = 0.56; 95% CI = 0.30–1.03). This is the first pharmacogenomic study of high-grade irAEs in an Asian population, identifying LINC01192 as a variant associated with severe irAEs. Our findings also highlight shared immune regulatory pathways between irAEs and autoimmune diseases, supporting the development of germline-based risk stratification to personalize ICI therapy.

Förderung

  • NMRC Clinician-Scientist Individual Research Grant New Investigator Grant
  • National University Hospital System Seed Fund 2022
  • NMRC Centre Grant Programme

Zitieren

APA

Huang, Y., Zhao, J. J., Wong, A., Tay, S. H., Soon, Y. Y., Ang, Y., Tan, C. L., Yang, S. P., Kee, A. C. L., Muthiah, M. D., Ng, K. W. P., Tan, L., Lee, J., Lahiri, M., Tang, M. S., Koo, C. Y., Quek, A. M. L., Chan, E., Yap, E. S., …, & Soo, R. A. (2026). Genetic susceptibility to severe immune-related adverse events from immune checkpoint inhibitors. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04640-4

Vancouver

Huang Y, Zhao JJ, Wong A, Tay SH, Soon YY, Ang Y, et al. Genetic susceptibility to severe immune-related adverse events from immune checkpoint inhibitors. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04640-4

BibTeX
@article{Huang2026,
  author = {Huang, Yiqing and Zhao, Joseph J. and Wong, Alvin and Tay, Sen Hee and Soon, Yu Yang and Ang, Yvonne and Tan, Chris Lixian and Yang, Samantha Peiling and Kee, Adrian C. L. and Muthiah, Mark D. and Ng, Kay W. P. and Tan, Li-Ling and Lee, Jonathan and Lahiri, Manjari and Tang, May Shuen and Koo, Chieh Yang and Quek, Amy M. L. and Chan, Esther and Yap, Eng Soo and Choo, Joan and Thong, Wei Sheng Edwin and Lim, Valencia and Ruparel, Mamta and Da, Yi and Teng, Margaret Li Peng and Wang, Lingzhi and Lwin, Thuya Win and Lee, Soo Chin and Jeyasekharan, Anand D. and Sim, Ming Yee and Bharwani, Lavina D. and Goh, Boon Cher and Kong, Li Ren and Aminkeng, Folefac and Soo, Ross A.},
  title = {Genetic susceptibility to severe immune-related adverse events from immune checkpoint inhibitors},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04640-4}
}
Kostenlos starten →